Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal Adenocarcinoma

Author(s): Sadaf Ghanaatgar-Kasbi, Shadi Khorrami, Amir Avan*, Seyed A. Aledavoud, Gordon A. Ferns*

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 39 , 2018

Become EABM
Become Reviewer
Call for Editor


The c-mesenchymal-epithelial transition factor (c-MET) is involved in the tumorigenesis of various cancers. HGF/Met inhibitors are now attracting considerable interest due to their anti-tumor activity in multiple malignancies such as pancreatic cancer. It is likely that within the next few years, HGF/Met inhibitors will become a crucial component for cancer management. In this review, we summarize the role of HGF/Met pathway in the pathogenesis of pancreatic cancer, with particular emphasize on HGF/Met inhibitors in the clinical setting, including Cabozantinib (XL184, BMS-907351), Crizotinib (PF-02341066), MK-2461, Merestinib (LY2801653), Tivantinib (ARQ197), SU11274, Onartuzumab (MetMab), Emibetuzumab (LY2875358), Ficlatuzumab (AV- 299), Rilotumumab (AMG 102), and NK4 in pancreatic cancer.

Keywords: c-mesenchymal-epithelial transition factor, HGF/Met inhibitors, pancreatic cancer, tumorigenesis, anti-tumor activity.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 14 March, 2019
Page: [4619 - 4625]
Pages: 7
DOI: 10.2174/1381612825666190110145855
Price: $65

Article Metrics

PDF: 35
HTML: 12
PRC: 1